Abstract-We studied 26 patients in a randomized, placebo-controlled, double-blind parallel trial to evaluate the efficacy and safety of donepezil in chronic poststroke aphasia. Donepezil (10 mg/day) improved aphasia severity at endpoint (week 16) relative to placebo (p ϭ 0.037). NEUROLOGY 2006;67:1687-1689 M.L. Berthier, MD, PhD; C. Green, PhD; C. Higueras, PhD; I. Ferná ndez, PhD; J. Hinojosa, PhD;
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After baseline evaluation, the patients were randomized in a 1:1 fashion, using a computer-generated random procedure, into donepezil (5 mg/day) or placebo during a 4-week titration phase, followed by a 12-week maintenance phase (10 mg/day of donepezil or placebo) with the possibility of dose adjustment to improve tolerability, and a 4-week washout phase. The procedures of allocation sequence, participant enrollment, and assignment of participants to trial groups were performed by different groups of people. Blinding was established with identical film-coated capsules containing 5 mg of either donepezil or placebo. Permitted concomitant medications included those agents that were clinically required before study recruitment to maintain and stabilize clinical status. Testing was performed at weeks 0, 4, 16 (endpoint), and 20 (washout). Standard SLT was provided for 2 hours per week and consisted of a syndromespecific standard approach. 3 Primary efficacy measures were the mean score change from baseline to endpoint (week 16) on Aphasia Quotient of the Western Aphasia Battery (WAB) 4 and Communicative Activity Log (CAL) (a scale that assesses the patient's communicative behavior in everyday life). 3 Secondary efficacy measures were subtests of the Psycholinguistic Assessment of Language Processing in Aphasia (PALPA) 5, 6 and the Stroke Aphasic Depression Questionnaire (SADQ). 7 Sample size and statistic analysis. The sample size was determined using the treatment effect size from our previous open-label trial of donepezil in PSA. 1 A two group t test with a 0.050 twosided significance level will have 80% power to detect a difference in means of 5,000 in AQ of the WAB, assuming that the common SD is 4,000 when the sample size in each group is 12. The 2 test was used for categorical variables and the independent sample t test (two-tailed) for continuous variables. Since this was a pilot study, multiple testing corrections (e.g., Bonferroni) were not performed. The data were analyzed by Euroclin Institute (Spain).
Results. The flow chart diagram of participants is represented in the figure. A total sample of 26 patients was recruited from February 2003 to November 2004. The completion rates for the study were 85% in each group. The donepezil and placebo groups were well-matched regarding baseline variables (table 1) and they did not differ in the use of concomitant medications.
The severity of aphasia (AQ of the WAB) improved more in the donepezil group than in the placebo group at endpoint (week 16) (donepezil: 6.4 Ϯ 3.8; 95% CI, 4.13 to 8.81; placebo: 3.5 Ϯ 2.7; 95% CI, 1.93 to 5.22; p ϭ 0.037) (table 2). These differences correspond to large effect sizes (Cohen's d ϭ 0.87). Comparison of the CAL did not reveal significant differences between baseline and endpoint. At post-washout testing, the donepezil group decreased its performance on the CAL relative to the placebo group when these scores were compared with those obtained at endpoint (donepezil: Ϫ4.6 Ϯ 8.6; 95% CI, Ϫ2.10 to 11.7; placebo: 4.8 Ϯ 4.5; 95% CI, 1.27 to 12.55, p ϭ 0.008).
The scores in the picture naming subtest of the PALPA improved more with donepezil at endpoint (4.6 Ϯ 5.8; 95% CI, 0.1 to 5.0) than with placebo (Ϫ1.0 Ϯ 6.3; 95% CI, Ϫ0.3 to 5.0) (p ϭ 0.025), a difference that corresponds to a large effect size (Cohen's d ϭ 0.92) (table 2). There were no between-group differences in other PALPA subtests nor in the SDAQ at endpoint.
Adverse events were higher in the donepezil group (8 patients, 61%) than in the placebo group (3 patients, 23%) ( 2 : 2.42, df: 1, p ϭ 0.119). Irritability (4 patients [30%]) and insomnia and tiredness (2 patients [15%]) were seen only during donepezil titration. Recurrence of poststroke seizures (2 patients [15%]) was seen during donepezil maintenance without relapsing after dose reduction. Adverse events in the placebo group included headache (n ϭ 1), abnormal dreams (n ϭ 1), and anorexia (n ϭ 1).
Discussion. In this study, donepezil significantly improved the AQ of the WAB and the picture naming subtest of the PALPA compared to placebo at endpoint. The CAL did not show significant donepezilplacebo differences between baseline and endpoint, but these between-group differences reached statistical significance when scores at 10 mg/day of donepezil (endpoint) were compared with lower doses (5 mg/day), suggesting that the beneficial effect of cholinergic therapy may be appreciable on measures of everyday communication.
Between-group differences were no longer significant at week 20 for most outcome measures, thus suggesting that donepezil enhances language and communication performance only when it is being taken. However, scores on outcome measures in post-washout testing for the donepezil group remained well above baseline scores and the attenuation of donepezil/placebo differences may have resulted from a good placebo response. Future studies should examine outcome variables using longer post-washout periods to detect whether the benefits of donepezil persist in a more durable fashion.
Acetylcholine acts as a cortical modulator playing a role in task-related plasticity and long-term potentiation necessary for learning, memory, language, and attention.
1,2 Cholinergic pathways are vulnerable to vascular damage. 8, 9 Localized left hemisphere strokes involving the insulo-opercular cortex, white matter tracts, or the mesial frontoparietal cortex in our patients presumably interrupted cholinergic projections en route to remote cortical sites necessary for language processing. 8, 9 Since neuronal activity is tightly coupled to vascular brain perfusion, it seems possible that the beneficial effect of donepezil in PSA outcome may be attributed to the improvement of neurovascular coupling. 9 A recent study found reduced levels of acetylcholinesterase in the CSF of anomic patients and that abnormalities in naming and the cholinergic marker were reversed by the cholinergic agent, bifemelane. 10 Additionally, preliminary evidence indicates that donepezil improves the regulation of regional cerebral blood flow in patients with vascular According to the WAB classification criteria 10 patients had Broca's aphasia (4 in the donepezil group and 6 in the placebo group), 9 patients had anomic aphasia (7 in the donepezil group and 2 in the placebo group), 4 patients had conduction aphasia (1 in the donepezil group and 3 in the placebo group), and 3 patients had Wernicke's aphasia (1 in the donepezil group and 2 in the placebo group). All but one patient had strokes in the left middle cerebral artery territory.
dementia. 9 Therefore, donepezil might restore the brain mechanisms for recovery from PSA, presumably by promoting both a reorganization of cortical networks 1,2 and a better control of regional cerebral blood flow regulation. 
